$LABT

Lakewood-Amedex Biotherapeutics shared preclinical data showing Nu-3's broad-spectrum activity and low resistance. The company is conducting a Phase 2a trial for diabetic foot ulcers, with results expected in Q1 2027. According to the company, the drug demonstrated rapid activity in tests.

Lakewood-Amedex Biotherapeutics (LABT) reported preclinical data showing its Bisphosphocin compound Nu-8 inhibited up to 97% of E. coli growth in rodents. Aerosol formulations also showed activity against pulmonary infections. The company plans further development to identify a clinical candidate. Nu-3 is in a Phase 2a trial for diabetic foot ulcers, with topline data expected in Q1 2027.

Lakewood-Amedex Biotherapeutics reported positive preclinical data for its Bisphosphocin® compounds, showing up to 97% inhibition of E. coli growth in urinary tract infections and activity against resistant bacteria in pulmonary infections. The company's lead candidate, Nu-3, is in a Phase 2a trial for diabetic foot ulcers, with results expected in Q1 2027. The Bisphosphocin® class aims to combat antibiotic-resistant strains.

Lakewood-Amedex Biotherapeutics Inc. (LABT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 22, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the record date of July 30, 2026, there were 2,369,688 shares of

Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial for Nu-3, a gel treating mildly infected diabetic foot ulcers. The trial will assess safety, efficacy, and optimal dosage. Results are expected in Q1 2027, with potential Phase 2b advancement if successful. According to the company, Nu-3 aims to reduce antimicrobial resistance by targeting infections locally.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has dosed the first patient in its Phase 2a clinical trial for Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy of three gel concentrations, with topline data expected in Q1 2027. Nu-3 is part of the company's Bisphosphocin® antimicrobial platform.

Lakewood-Amedex Biotherapeutics (LABT) reported Q2 2026 progress, including Nasdaq listing, $7.5M private placement, and Nu-3 Gel Phase 2a trial prep. The company expanded its IP portfolio and appointed David G. Armstrong as Study Chair. LABT aims to advance Nu-3 for infected diabetic foot ulcers, with clinical trial initiation expected soon.

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and clinical site readiness to start a Phase 2a trial for its lead product, Nu-3, treating infected diabetic foot ulcers. The trial aims to evaluate Nu-3's safety and efficacy, building on positive preclinical data. The company aims to address antibiotic-resistant bacterial strains with its Bisphosphocin® class of antimicrobials.

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and confirmed clinical site readiness to start a Phase 2a trial for Nu-3, a treatment for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy, building on positive preclinical data. The company focuses on addressing antibiotic-resistant bacterial infections with its Bisphosphocin® class of antimicrobials.

A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.